Sylvester Comprehensive Cancer Center

  • 20201130 - Alderuccio Juan

  • Investigator:
    Juan Alderuccio
    RCname Email

    		Coordinator:

    IRB: 20201130

    		SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma
    Sponsor: SCCC

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Plantation
    Sylvester
    UMH
    Title:

    Single-arm, open-label phase 2 study of loncastuximab tesirine in combination with rituximab in patients with advanced stage follicular lymphoma
    Eligibility Criteria - NCT04998669 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230567 - Alderuccio Juan

  • Investigator:
    Juan Alderuccio
    RCname Email

    		Coordinator:

    IRB: 20230567

    		SDG: Lymphoma
    Disease Site(s):

    Multiple
    Sponsor: NOVARTIS

    Enrolling Sites:

    Sylvester
    UMH
    Title:

    A phase I, open-label, multi-center study of PIT565 in patients with relapsed and/or refractory B-cell malignancies
    Eligibility Criteria - NCT05397496 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230696 - Alderuccio Juan

  • Investigator:
    Juan Alderuccio
    RCname Email

    		Coordinator:

    IRB: 20230696

    		SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma
    Sponsor: ADC THERAPEUTICS

    Enrolling Sites:

    Aventura
    Deerfield
    Doral
    Gables
    Hollywood
    Plantation
    Sylvester
    UMH
    Title:

    A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
    Eligibility Criteria - NCT04970901 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230724 - Alderuccio Juan

  • Investigator:
    Juan Alderuccio
    RCname Email

    		Coordinator:

    IRB: 20230724

    		SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma
    Sponsor: DANA-FARBER CANCER INSTITUTE

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Hollywood
    Plantation
    Sylvester
    UMH
    Title:

    A phase II study of glofitamab plus polatuzumab-R-CHP for patients with high-risk diffuse large B-cell lymphoma
    Eligibility Criteria - NCT05800366 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231098 - Alderuccio Juan

  • Investigator:
    Juan Alderuccio
    RCname Email

    		Coordinator:

    IRB: 20231098

    		SDG: Lymphoma
    Disease Site(s):

    Multiple
    Sponsor: ASTRA ZENECA

    Enrolling Sites:

    Sylvester
    UMH
    Title:

    PRIMAVERA: A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agent(s) in Participants With Relapsed/Refractory Haematologic Malignancies
    Eligibility Criteria - NCT06137144 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240458 - Alderuccio Juan

  • Investigator:
    Juan Alderuccio
    RCname Email

    		Coordinator:

    IRB: 20240458

    		SDG: Lymphoma
    Disease Site(s):

    Brain and Nervous System
    Sponsor: SCCC

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Doral
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    Zanubrutinib in Combination with Pola-R-CHP and High-dose Methotrexate in Patients with Secondary CNS Lymphoma
    Eligibility Criteria - NCT06730542 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210550 - Alencar Alvaro

  • Investigator:
    Alvaro Alencar
    RCname Email

    		Coordinator:

    IRB: 20210550

    		SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma
    Sponsor: Alliance

    Enrolling Sites:

    ABLEH
    Deerfield
    Gables
    Plantation
    Sylvester
    UMH
    Title:

    Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma
    Eligibility Criteria - NCT04609046 *This information has been extracted from " www.clinicaltrials.gov"

  • 20221346 - Alencar Alvaro

  • Investigator:
    Alvaro Alencar
    RCname Email

    		Coordinator:

    IRB: 20221346

    		SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma
    Sponsor: SCCC

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    Title:

    A phase 1/2 study of Zanubrutinib and Tafasitamab in mantle cell lymphoma
    Eligibility Criteria - NCT06029309 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230461 - Alencar Alvaro

  • Investigator:
    Alvaro Alencar
    RCname Email

    		Coordinator:

    IRB: 20230461

    		SDG: Lymphoma
    Disease Site(s):

    Multiple
    Sponsor: Nurix Therapeutics

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester
    UMH
    Title:

    A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Brutons Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies
    Eligibility Criteria - NCT05131022 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231244 - Alencar Alvaro

  • Investigator:
    Alvaro Alencar
    RCname Email

    		Coordinator:

    IRB: 20231244

    		SDG: Lymphoma
    Disease Site(s):

    Multiple
    Sponsor: Ono Pharma Inc

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    UMH
    Title:

    An open-label phase II study to investigate the efficacy, safety, and pharmacokinetics of tirabrutinib in patients with Primary Central Nervous System Lymphoma (PCNSL)
    Eligibility Criteria - NCT04947319 *This information has been extracted from " www.clinicaltrials.gov"

  • 20221298 - Crane Tracy

  • Investigator:
    Tracy Crane
    RCname Email

    		Coordinator:

    IRB: 20221298

    		SDG: Lymphoma
    Disease Site(s):

    Multiple
    Sponsor: SCCC

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Doral
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    Lifestyle Intervention of Food and Exercise for Lymphoma Survivors (LIFE - L)
    Eligibility Criteria - NCT05839210 *This information has been extracted from " www.clinicaltrials.gov"

  • 20211204 - Lossos Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    		Coordinator:

    IRB: 20211204

    		SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma
    Sponsor: SCCC

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester
    Title:

    A phase 2, open-label, study evaluating safety and efficacy of the loncastuximab in relapsed/refractory marginal zone lymphoma
    Eligibility Criteria - NCT05296070 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231248 - Lossos Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    		Coordinator:

    IRB: 20231248

    		SDG: Lymphoma
    Disease Site(s):

    Multiple
    Sponsor: Hoffmann - La Roche

    Enrolling Sites:

    Deerfield
    Gables
    Hollywood
    Plantation
    Sylvester
    UMH
    Title:

    A Phase III, Open-Label, Multicenter Randomized Study Evaluating Glofitamab as a Single Agent Versus Investigator's Choice in Patients With Relapsed/Refractory Mantle Cell Lymphoma
    Eligibility Criteria - NCT06084936 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240178 - Lossos Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    		Coordinator:

    IRB: 20240178

    		SDG: Lymphoma
    Disease Site(s):

    Multiple
    Sponsor: SCCC

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester
    UMH
    Title:

    Phase II trial of Mosunetuzumab in patients with newly diagnosed Extranodal Marginal Zone Lymphoma (EMZL) (ML44933)
    Eligibility Criteria - NCT06569680 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190755 - Moskowitz Craig

  • Investigator:
    Craig Moskowitz
    RCname Email

    		Coordinator:

    IRB: 20190755

    		SDG: Lymphoma
    Disease Site(s):

    Hodgkin Lymphoma
    Sponsor: Memorial Sloan-Kettering Cancer Center

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    Title:

    Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
    Eligibility Criteria - NCT03618550 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230081 - Moskowitz Craig

  • Investigator:
    Craig Moskowitz
    RCname Email

    		Coordinator:

    IRB: 20230081

    		SDG: Lymphoma
    Disease Site(s):

    Hodgkin Lymphoma
    Sponsor: SCCC

    Enrolling Sites:

    Deerfield
    Gables
    Stanford University
    Sylvester
    UMH
    Title:

    A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previously untreated stage IA/IIA Hodgkin lymphoma
    Eligibility Criteria - NCT04685616 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231251 - Moskowitz Craig

  • Investigator:
    Craig Moskowitz
    RCname Email

    		Coordinator:

    IRB: 20231251

    		SDG: Lymphoma
    Disease Site(s):

    Multiple
    Sponsor: Seagen Inc

    Enrolling Sites:

    Gables
    Sylvester
    UMH
    Title:

    An open-label phase 1 study to evaluate the safety of SGN-35T in adults with advanced malignancies
    Eligibility Criteria - NCT06120504 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240391 - Moskowitz Craig

  • Investigator:
    Craig Moskowitz
    RCname Email

    		Coordinator:

    IRB: 20240391

    		SDG: Lymphoma
    Disease Site(s):

    Hodgkin Lymphoma,Non-Hodgkin Lymphoma
    Sponsor: Seagen Inc

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Plantation
    Sylvester
    Title:

    A phase 1, open-label study to evaluate SGN-35C in adults with advanced malignancies.
    Eligibility Criteria - NCT06254495 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240836 - Moskowitz Craig

  • Investigator:
    Craig Moskowitz
    RCname Email

    		Coordinator:

    IRB: 20240836

    		SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma
    Sponsor: SWOG

    Enrolling Sites:

    Coral Springs
    Deerfield
    Doral
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    Title:

    Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
    Eligibility Criteria - NCT06337318 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240911 - Moskowitz Craig

  • Investigator:
    Craig Moskowitz
    RCname Email

    		Coordinator:

    IRB: 20240911

    		SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma
    Sponsor: ETCTN

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Doral
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    NORM: Nodular Lymphocyte-Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase 2 Trial with Either Rituximab or Mosunetuzumab
    Eligibility Criteria - NCT05886036 *This information has been extracted from " www.clinicaltrials.gov"

  • 20250293 - Moskowitz Craig

  • Investigator:
    Craig Moskowitz
    RCname Email

    		Coordinator:

    IRB: 20250293

    		SDG: Lymphoma
    Disease Site(s):

    Hodgkin Lymphoma
    Sponsor: SCCC

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Doral
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    A Phase 2 Trial of Abbreviated Brentuximab Vedotin, Etoposide, Cyclophosphamide, Adriamycin, Dacarbazine, and Dexamethasone (BrECADD) Therapy in Stage IIB-IV Hodgkin Lymphoma
    Eligibility Criteria - NCT07002216 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230797 - Pongas Georgios

  • Investigator:
    Georgios Pongas
    RCname Email

    		Coordinator:

    IRB: 20230797

    		SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma
    Sponsor: BEIGENE

    Enrolling Sites:

    Deerfield
    Gables
    Hollywood
    Plantation
    Sylvester
    Title:

    An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination with Zanubrutinib (BGB-3111) in Patients With Waldenstrm Macroglobulinemia
    Eligibility Criteria - NCT05952037 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231159 - Pongas Georgios

  • Investigator:
    Georgios Pongas
    RCname Email

    		Coordinator:

    IRB: 20231159

    		SDG: Lymphoma
    Disease Site(s):

    Multiple
    Sponsor: City of Hope

    Enrolling Sites:

    Coral Springs
    Deerfield
    Doral
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    A Phase 2 study with a safety lead-in of the anti-CD19 antibody tafasitamab with the BTK inhibitor zanubrutinib in newly diagnosed chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) TaZa CLL Study
    Eligibility Criteria - NCT05718869 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230192 - Ramos Juan Carlos

  • Investigator:
    Juan Carlos Ramos
    RCname Email

    		Coordinator:

    IRB: 20230192

    		SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma
    Sponsor: AMC

    Enrolling Sites:

    Deerfield
    Doral
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    A Multicenter, Open-label Feasibility Study of Daratumumab with Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma with or without HIV
    Eligibility Criteria - NCT04139304 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231198 - Ramos Juan Carlos

  • Investigator:
    Juan Carlos Ramos
    RCname Email

    		Coordinator:

    IRB: 20231198

    		SDG: Lymphoma
    Disease Site(s):

    Multiple
    Sponsor: AMC

    Enrolling Sites:

    Deerfield
    Kendall
    Plantation
    Sylvester
    Title:

    A Phase 2 Trial of Ixazomib for Kaposi Sarcoma
    Eligibility Criteria - NCT04305691 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220155 - Schatz Jonathan

  • Investigator:
    Jonathan Schatz
    RCname Email

    		Coordinator:

    IRB: 20220155

    		SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma
    Sponsor: Alliance

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    A RANDOMIZED PHASE II STUDY OF CHO(E)P VS CC-486-CHO(E)P VS DUVELISIB-CHO(E)P IN PREVIOUSLY UNTREATED CD30 NEGATIVE PERIPHERAL T-CELL LYMPHOMAS
    Eligibility Criteria - NCT04803201 *This information has been extracted from " www.clinicaltrials.gov"

  • 20240524 - Schatz Jonathan

  • Investigator:
    Jonathan Schatz
    RCname Email

    		Coordinator:

    IRB: 20240524

    		SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma
    Sponsor: CP

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    UMH
    Title:

    A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physicians Choice Standard of Care Treatment (Selected Single Agent) in Participants with Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
    Eligibility Criteria - NCT06561048 *This information has been extracted from " www.clinicaltrials.gov"